Immunotherapy Coverage from Every Angle

Recent News

Nivolumab Plus Cabozantinib Approved by FDA for Advanced Renal Cell Carcinoma
JAVELIN Medley VEGF: Monoclonal Antibody Plus VEGFR Inhibitor Studied in NSCLC
Immunotherapy After Nephrectomy Under Study in Localized Renal Cell Carcinoma
Lisocabtagene Maraleucel for Resistant CLL: Phase I Trial Update
Avelumab Plus Axitinib Under Study in Urothelial Cancer
Tiragolumab Combination Treatment Granted Breakthrough Therapy Designation in NSCLC
Early Study of Lisocabtagene Maraleucel Plus Ibrutinib in Resistant CLL
Preclinical Trial Explores Anti–PD-1 Strategies for Triple-Negative Breast Cancer
Can Chemoimmunotherapy Achieve Pathologic Downstaging in Resectable Lung Cancer?
Investigational Immunotherapy Focus of Phase I Trial in Resistant Myeloma
Combination Immunotherapy for Urothelial Carcinoma: Phase Ib Interim Analysis
Case Study of Rare but Aggressive Immune-Related Adverse Events in Kidney Cancer
Trop-2 Expression and Sacituzumab Govitecan in Triple-Negative Breast Cancer
Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: OMNIVORE Trial
ASH 2020: Intravenous and Subcutaneous Teclistamab for Resistant Multiple Myeloma
DDR Alterations and Outcomes With Immunotherapy for Advanced Urothelial Cancer
SABCS 2020: Pembrolizumab Plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
ASH 2020: Ciltacabtagene Autoleucel Under Study in Resistant Myeloma
IL-7 After Sipuleucel-T for Advanced Prostate Cancer
Daratumumab Plus Pomalidomide and Low-Dose Dexamethasone in Myeloma: Immune-Mediated Cytotoxicity
JAVELIN Bladder 100: Avelumab Maintenance for Advanced Urothelial Carcinoma
Novel Chemoimmunotherapy Regimen Under Study in Recurrent Ovarian Cancer
ASH 2020: Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone in Resistant Myeloma
ADP-A2M10 Dose-Escalation Trial in MAGE-A10–Positive Urothelial Tumors
Ramucirumab Plus Osimertinib in NSCLC: Final Analysis of Phase I Trial
ASH 2020: PI3K Inhibitor Plus Monoclonal Antibody Versus Chemoimmunotherapy for CLL
Potential Predictive Markers and/or Therapeutic Targets in Merkel Cell Carcinoma
HER2-Targeting Antibody-Drug Conjugate in Advanced Urothelial Carcinoma
ASH 2020: Novel Immunotherapy Plus Chemotherapy in Resistant Multiple Myeloma
ASH 2020: Early Results in Targeting CD47 in AML
FDA Brief: Eprenetapopt Given Fast Track Designation for TP53-Mutant AML
ESMO Asia 2020: MONARCH 2 Update on Abemaciclib Plus Fulvestrant in East Asian Patients With Breast Cancer
ASH 2020: BCMA-Targeted Antibody-Drug Conjugate in Resistant Multiple Myeloma
Are High 12-Chemokine Scores Prognostic in Muscle-Invasive Bladder Cancer?
Immunochemotherapy for Metastatic Castration-Resistant Prostate Cancer: KEYNOTE-365 Cohort B Update
Neoadjuvant Ipilimumab Plus Nivolumab Under Study in Urothelial Carcinoma
ESMO Asia 2020: Subgroup Analysis of KEYNOTE-522 Supports Use of Pembrolizumab in Triple-Negative Breast Cancer
SITC 2020: Tumor Mutation Burden and Response to Immunotherapy in Advanced Urothelial Cancer
SITC 2020: Bemcentinib and Pembrolizumab in Stage IV Lung Adenocarcinoma
SITC 2020: Checkpoint Inhibitor Pair Tested in Thyroid Malignancies

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.